| Drug Name |
Dalbavancin |
| Drug ID |
BADD_D00572 |
| Description |
Dalbavancin is a second-generation lipoglycopeptide antibiotic that was designed to improve on the natural glycopeptides currently available, such as vancomycin and teicoplanin [A4072, A4073]. Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073]. Its use is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, S. dysgalactiae, the S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin susceptible strains) [FDA Label, F2356]. Dalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072, A4073]. |
| Indications and Usage |
Dalbavancin is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by the following gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), S. pyogenes, S. agalactiae, and S. anginosus group (including S. anginosus, S. intermedius, and S. constellatus). It is administered as a 30 minute IV infusion in a two-dose regimen of 1000 mg followed by 500 mg one week later. |
| Marketing Status |
Prescription |
| ATC Code |
J01XA04 |
| DrugBank ID |
DB06219
|
| KEGG ID |
D03640
|
| MeSH ID |
C469289
|
| PubChem ID |
16134627
|
| TTD Drug ID |
D07QAR
|
| NDC Product Code |
57970-100; 82297-102 |
| Synonyms |
dalbavancin | Zeven | BI-397 | BI397 | BI 397 | MDL 64,397 | MDL-64397 | Dalvance | A-A-1 antibiotic | Xydalba | VER-001 | VER001 |
